T100: nebulized-concentrated tobramycin formulation for treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients

Introduction: Chronic lung infection with Pseudomonas aeruginosa (PsA) is associated with more rapid pulmonary decline and acute pulmonary exacerbations in patients with cystic fibrosis (CF). The treatment of airway infection with this organism is particularly challenging and is the focus of many therapeutic interventions. Inhaled antibiotics targeting PsA infection are useful for eradication of PsA as well as management of chronic infection. Areas covered: Herein, we discuss currently available inhaled antibiotics for management of lung infections in CF patients, with a focus on nebulized-concentrated tobramycin (NCT). Results from relevant articles published in the English language are included. Expert opinion: NCT is a concentrated formulation of tobramycin with pharmacokinetics and safety profile similar to tobramycin inhalation solution. Results of a recent trial suggest that NCT may be an attractive inhaled antibiotic to manage CF PsA lung infections, with the capacity for shorter administration time, higher pulmonary drug concentrations and reduced systemic bioequivalence compared to tobramycin inhalation solution.